Tag Archives: Biocartis Group

Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of its second liquid biopsy assay, the Idylla(TM) ...

Read More »